Abstract | PURPOSE: PATIENTS AND METHODS: Retrospective analysis of pretreatment and follow-up magnetic resonance imaging (MRI) data for 451 patients with NPC treated with IMRT at a single institution. The diagnosis of mastoiditis was based on MRI; otomastoid opacification was rated as Grade 0 (none), 1 (mild), 2 (moderate) or 3 (severe) by radiologists blinded to clinical outcome. This study mainly focused on severe mastoiditis; patients were divided into three groups: the G0M (Grade 0 mastoiditis before treatment) group, G1-2M (Grade 1 to 2 mastoiditis before treatment) group and G3M (Grade 3 mastoiditis before treatment) group. The software SAS9.3 program was used to analyze the data. RESULTS: For the entire cohort, the incidence of Grade 3 mastoiditis was 20% before treatment and 31%, 19% and 17% at 3, 12 and 24 months after radiotherapy, respectively. In the G0M group, the incidence of severe mastoiditis was 0% before treatment and 23%, 15% and 13% at 3, 12 and 24 months after radiotherapy, respectively. Multivariate analysis revealed T category (OR=0.68, 95% CI = 0.469 to 0.984), time (OR=0.668, 95% CI = 0.59 to 0.757) and chemotherapy (OR=0.598, 95% CI = 0.343 to 0.934) were independent factors associated with severe mastoiditis in the G0M group after treatment. CONCLUSIONS:
Mastoiditis, as diagnosed by MRI, occurs as a progressive process that regresses and resolves over time in patients with NPC treated using IMRT.
|
Authors | Ji-Jin Yao, Guan-Qun Zhou, Xiao-Li Yu, Ling-Long Tang, Lei Chen, Yan-Ping Mao, Li Lin, Lu-Lu Zhang, Jian-Yong Shao, Ying Guo, Jun Ma, Ying Sun |
Journal | PloS one
(PLoS One)
Vol. 10
Issue 6
Pg. e0131284
( 2015)
ISSN: 1932-6203 [Electronic] United States |
PMID | 26114761
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Aged
- Carcinoma
- Female
- Humans
- Incidence
- Male
- Mastoiditis
(epidemiology, etiology)
- Middle Aged
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
(epidemiology, radiotherapy)
- Radiation Injuries
(epidemiology)
- Radiotherapy, Intensity-Modulated
(adverse effects)
- Risk Factors
|